Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of umeclidinium added to fluticasone furoate in COPD with an asthmatic component
2014-000883-16Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of umeclidinium and fluticasone in chronic obstructive pulmonary disease (COPD) and Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome (ACOS) (6 arms), sponsored by GSK. Primary endpoint: Change from baseline in clinic trough FEV1. Started Apr 2014; status: completed.
02
Drugs
umeclidiniumfluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome (ACOS)
Beyond the preview
Go deeper on 2014-000883-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000883-16.